Ann: Kazia licenses Cantrixil to Oasmia, page-3

Board of DirectorsMr Iain Ross Chairman,Non-Executive DirectorMr Bryce Carmine Non-Executive DirectorMr Steven Coffey Non-Executive DirectorDr James Garner Chief Executive Officer, Managing DirectorThree International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000ASX RELEASE1 March2021KAZIA LICENSES CANTRIXIL, A CLINICAL-STAGE, FIRST-IN-CLASSOVARIAN CANCER DRUG CANDIDATE, TO OASMIA PHARMACETICAL ABSydney,1 March2021–Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce thatit has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB(STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1), a clinical-stage, first-in-class drug candidate under development for the treatment of ovarian cancer.Key Points•Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer•Under the terms of the agreement, Oasmia will makean upfront payment ofUS$ 4millionto Kazia, with contingent milestonepaymentsof up to US$ 42million, and double-digit royalties on commercial sales•Oasmia is an innovative specialty pharmaceutical company, based in Stockholm, Sweden. Itslead product, Apealea®(paclitaxel micellar), is approved in Europe for adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, and is in late-stage clinical development in the US•Oasmia expectsto commence aPhase II study of Cantrixil in ovarian cancer in 2022Kazia CEO, Dr James Garner, commented, “Oasmia possesses deep expertise in the field of ovarian cancer, and also brings to Cantrixil a highly commercial focus, world-classformulation capabilities, and an extensive network of clinician relationships in Europe and the US.This transaction follows the release of very encouraging top-line data from the phase I study ofCantrixil late last year. Our strategy has been to seek a partner for Cantrixil’s further development, and we are delighted to now pass the baton to the Oasmia team.”